Characterization of COVID-19 Hospitalized Patients in Three United States Electronic Health Record Databases

被引:2
|
作者
Saunders-Hastings, Patrick [1 ]
Zhou, Cindy Ke [2 ]
Hobbi, Shayan [3 ]
Boyd, Eva [1 ]
Lloyd, Patricia [2 ]
Alawar, Nader [3 ]
Burrell, Timothy [3 ]
Beers, Jeff [3 ]
Clarke, Tainya C. C. [2 ]
Hettinger, Aaron Z. Z. [4 ]
Wong, Hui-Lee [2 ]
Shoaibi, Azadeh [2 ]
机构
[1] Gev Consulting Inc, Ottawa, ON K1P 1A4, Canada
[2] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA
[3] IBM Consulting, Bethesda, MD 20814 USA
[4] MedStar Hlth Res Inst, Ctr Biostat Informat & Data Sci, Hyattsville, MD 20782 USA
来源
PATHOGENS | 2023年 / 12卷 / 03期
关键词
COVID-19; hospitalization; EHR; epidemiology; treatment; United States; EPIDEMIOLOGY; OUTCOMES; ADULTS;
D O I
10.3390/pathogens12030390
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
COVID-19 infections have contributed to substantial increases in hospitalizations. This study describes demographics, baseline clinical characteristics and treatments, and clinical outcomes among U.S. patients admitted to hospitals with COVID-19 during the prevaccine phase of the pandemic. A total of 20,446 hospitalized patients with a positive COVID-19 nucleic acid amplification test were identified from three large electronic health record databases during 5 February-30 November 2020 (Academic Health System: n = 4504; Explorys; n = 7492; OneFlorida: n = 8450). Over 90% of patients were >= 30 years of age, with an even distribution between sexes. At least one comorbidity was recorded in 84.6-96.1% of patients; cardiovascular and respiratory conditions (28.8-50.3%) and diabetes (25.6-44.4%) were most common. Anticoagulants were the most frequently reported medications on or up to 28 days after admission (44.5-81.7%). Remdesivir was administered to 14.1-24.6% of patients and increased over time. Patients exhibited higher COVID-19 severity 14 days following admission than the 14 days prior to and on admission. The length of in-patient hospital stay ranged from a median of 4 to 6 days, and over 85% of patients were discharged alive. These results promote understanding of the clinical characteristics and hospital-resource utilization associated with hospitalized COVID-19 over time.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States
    Daniel Sheinson
    Joseph Dang
    Anuj Shah
    Yang Meng
    David Elsea
    Stacey Kowal
    Advances in Therapy, 2021, 38 : 1811 - 1831
  • [22] Characteristics and outcomes of kidney transplant patients hospitalized for COVID-19 in the United States.
    Mozaffari, Essy
    Chandak, Aastha
    Kalil, Andre C.
    Chima-Melton, Chidinma
    Amin, Alpesh N.
    Berry, Mark
    Okulicz, Jason F.
    Gottlieb, Robert L.
    TRANSPLANTATION, 2024, 108 (09) : 81 - 81
  • [23] Real world use of anticoagulation among hospitalized patients with COVID-19 in the United States
    Bates, Benjamin
    Lee, Eileen
    Kuhrt, Nathaniel
    Xu, Chang
    Setoguchi, Soko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 79 - 80
  • [24] A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States
    Sheinson, Daniel
    Dang, Joseph
    Shah, Anuj
    Meng, Yang
    Elsea, David
    Kowal, Stacey
    ADVANCES IN THERAPY, 2021, 38 (04) : 1811 - 1831
  • [25] Trends in administered medication use among patients hospitalized with COVID-19 in the United States
    Ogilvie, Rachel P.
    Doherty, Michael C.
    Clifford, Robin
    Gately, Robert V.
    Liang, Caihua
    Chomistek, Andrea K.
    Wang, Florence
    Seeger, John D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 375 - 376
  • [26] Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19
    Rosenberg, Eli S.
    Holtgrave, David R.
    Udo, Tomoko
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 99 : 38 - 39
  • [27] Characterization of test positivity among patients with coronavirus disease 2019 (COVID-19) in three electronic health records databases, February–November 2020
    Patrick Saunders-Hastings
    Cindy Ke Zhou
    Shayan Hobbi
    Hui-Lee Wong
    Patricia Lloyd
    Eva Boyd
    Nader Alawar
    Tainya C. Clarke
    Jeff Beers
    Timothy Burrell
    Azadeh Shoaibi
    BMC Public Health, 22
  • [28] The impact of COVID-19 and the COVID-19 pandemic on hospitalized patients with STEMI in the United States: insights from the National Inpatient Sample
    Kwok, Chun Shing
    Qureshi, Adnan I.
    Will, Maximillian
    Schwartz, Konstatin
    Borovac, Josip A.
    Waters, David
    Potluri, Rahul
    Lip, Gregory Y. H.
    CORONARY ARTERY DISEASE, 2024, 35 (01) : 23 - 30
  • [29] Leveraging the Electronic Health Record to Address the COVID-19 Pandemic
    Satter, Benjamin A.
    Dikilitas, Ozan
    Kullo, Iftikhar J.
    MAYO CLINIC PROCEEDINGS, 2021, 96 (06) : 1592 - 1608
  • [30] Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19
    Magagnoli, Joseph
    Narendran, Siddharth
    Pereira, Felipe
    Cummings, Tammy H.
    Hardin, James W.
    Sutton, S. Scott
    Ambati, Jayakrishna
    MED, 2020, 1 (01): : 114 - +